大肠癌是消化道常见的恶性肿瘤之一,其发病率呈逐年上升趋势,其治疗失败的主要原因是大肠癌的肝转移。为探讨大肠癌5—氟脲嘧啶(5—Fu)门静脉插管化疗预防大肠癌术后肝转移的价值,1994年8月由中英两国专家合作,开始了本项课题的国际间大规模临床协作研究,河北医科大学第三医院大肠科作为首批参加单位同期开始了此项研究。全部研究计划3～5年完成1万例临床研究,其中我国完成500例。 凡确诊为大肠腺癌者;无肝或远处转移者;肿瘤可以根治切除者均为研究对象,本研究共设两个组即化疗组与非化疗组。病人于根治切除术完成关腹前行双育随机分组,决定是否进行门静脉插管。分入插管组病人按静脉切开步骤行门静脉插管,术后回房开始经导管24小时连续滴注5—Fu,每日1g,共7天,化疗完毕缓慢拔除导和即可。 Colorectal cancer is one of the common malignancies in the digestive tract. The incidence of colorectal cancer is increasing year by year. The main reason for treatment failure is liver metastasis of colorectal cancer. To investigate the value of 5-fluorouracil (5-Fu) portal vein catheterization for preventing colorectal cancer liver metastasis in colorectal cancer, an international large-scale clinical trial was initiated in August 1994 by experts from China and the United Kingdom. Collaborative research, the third group of Hebei Medical University Hospital as the first batch of participants in the same period began the study. All research plans have completed 10,000 clinical studies in 3 to 5 years, of which 500 cases have been completed in China. Those diagnosed with colorectal adenocarcinoma; no liver or distant metastasis; tumor can be radical resection are all subjects of study, the study set a total of two groups that chemotherapy and non-chemotherapy group. The patients were randomly divided into double-birth groups before radical resection was completed and they were determined whether to perform portal vein catheterization. Patients in the intubation group were treated by portal vein venous cannulation through a venous incision procedure. After the operation, 5-Fu was continuously infused through the catheter for 24 hours, and 1 g daily for 7 days. After the chemotherapy was completed, the catheter was removed.